Bio/Pharma Business

Discovery Life Sciences Acquires AllCells

July 26, 2022

Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.

AstraZeneca to Acquire TeneoTwo in Deal Worth Up to $1.26 Billion

July 26, 2022

AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.

Merck and Orion Announce Global Collaboration for Oncology Drug

July 25, 2022

Merck, known as MSD outside the United States and Canada, and Orion Corporation are collaborating to develop and commercialize a treatment for metastatic castration-resistant prostate cancer.

Cytiva Acquires Chromatography Resins Manufacturing Facility in Muskegon, Michigan

July 19, 2022

Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.

Royalty Pharma Acquires Royalty Rights to COPD/Asthma Treatment for $1.6 Billion

July 18, 2022

Royalty Pharma is paying $1.6 billion for the royalty rights to Trelegy Ellipta, a treatment for COPD and asthma.

Vertex to Acquire ViaCyte for $320 Million

July 18, 2022

Vertex’s $320 million acquisition of ViaCyte will give the company complementary capabilities for its Type 1 diabetes therapy program.

Merck Digital Sciences Studio Supports Early-Stage Startups

July 13, 2022

Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.

Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA

July 13, 2022

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Wacker Biotech Expands Germany Site with Construction of New mRNA Competence Center

July 12, 2022

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

Coya Therapeutics Secures Rights to Exosome Engineering Technology from Carnegie Mellon University

July 08, 2022

Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.